





Münster, 15.5.2014

Psychische Krankheit: Modelle der Neurobiologie und Genetik


Andreas Meyer-Lindenberg ML
Zentralinstitut für Seelische Gesundheit, Mannheim





Kosten neuropsychiatrischer Krankheiten in Europa 2010 (€ PPP Mio)







Gene und Umwelt: Kausalfaktoren des Erkrankungsrisikos



Gene




Umwelt





Soziales Umfeld und Langlebigkeit




Stadt-Land-Unterschiede


Table 2: Prevalence of psychiatric disorders in the last 12 months in adults (18–65 years of age) in Germany in relation to urbanization in 1999 (weighted percentages with standard error)

	Urbanization										p for trend	
	Extremely urban		Very Urban		Urban		Rural		Very Rural			
	N = 1169	%	N = 849	%	N = 888	%	N = 661	%	N = 614	%		
any mood disorders	15.2% (178)	1.1%	12.4% (105)	1.2%	10.6% (94)	1.0%	9.8% (65)	1.1%	9.3% (57)	1.1%	.000	
major depressive disorder	11.1% (130)	0.9%	7.7% (65)	1.0%	6.9% (61)	0.8%	7.5% (50)	1.0%	6.8% (42)	1.0%	.001	
any bipolar disorder	1.2% (14)	0.3%	1.2% (10)	0.4%	0.5% (4)	0.2%	0.5% (3)	0.3%	0.3% (2)	0.2%	-.*	
dysthymia	4.8% (56)	0.6%	5.4% (46)	0.8%	4.6% (41)	0.7%	3.7% (24)	0.7%	3.2% (20)	0.7%	.047	
any anxiety disorders	16.9% (198)	1.1%	12.6% (107)	1.2%	14.8% (131)	1.1%	14.3% (95)	1.4%	12% (74)	1.3%	.024	
social phobia	2.6% (30)	0.5%	2% (17)	0.5%	1.5% (13)	0.4%	2.5% (17)	0.6%	1.1% (7)	0.4%	.086	
any simple phobia	7.9% (92)	0.8%	7.2% (61)	0.9%	7.3% (65)	0.8%	7.6% (50)	1.0%	8.2% (50)	1.1%	.895	
generalized anxiety disorder	2.1% (25)	0.4%	1.3% (11)	0.4%	1.5% (13)	0.4%	1.3% (9)	0.4%	0.9% (6)	0.4%	.065	
obsessive compulsive disorder	0.9% (11)	0.3%	1.1% (9)	0.4%	0.8% (7)	0.3%	0.4% (3)	0.3%	0.1% (1)	0.1%	-.*	
panic disorder with/without agoraphobia	2.7% (32)	0.5%	2.6% (22)	0.6%	2.4% (21)	0.5%	2.4% (16)	0.6%	1.3% (8)	0.4%	.098	
any somatoform disorder/syndrome	13.7% (160)	1.0%	13.5% (115)	1.2%	9.7% (86)	1.0%	8.2% (54)	1.1%	7.4% (45)	1.0%	.000	
SSI4.6	5.6% (65)	0.7%	5.9% (50)	0.8%	3.3% (29)	0.6%	2.9% (19)	0.6%	2.8% (17)	0.6%	.000	
pain disorder	9.8% (115)	0.9%	9.7% (82)	1.1%	7.6% (67)	0.9%	6.5% (43)	1.0%	5.4% (33)	0.9%	.000	
any substance disorder	5.1% (60)	0.7%	3.7% (31)	0.7%	3.6% (32)	0.6%	4.9% (32)	0.8%	5.1% (31)	0.8%	.920	
alcohol abuse or dependence	4.3% (50)	0.6%	3.8% (32)	0.7%	3.1% (28)	0.6%	4.9% (32)	0.8%	4.7% (29)	0.8%	.556	
alcohol dependence	3.4% (40)	0.5%	3.1% (26)	0.6%	2.3% (20)	0.5%	4.3% (28)	0.8%	4% (25)	0.8%	.386	
illicit drug abuse/dependence	1% (12)	0.3%	0.5% (4)	0.3%	0.8% (7)	0.3%	0.2% (1)	0.2%	0.8% (5)	0.3%	-.*	
possible psychotic disorder	2.4% (28)	0.5%	3.5% (30)	0.7%	2.6% (23)	0.5%	2.7% (18)	0.6%	1.4% (9)	0.5%	.208	
any mental disorder	36.4% (426)	1.5%	31% (263)	1.7%	29.4% (261)	1.5%	28.3% (187)	1.7%	26.6% (163)	1.7%	.000	

Stadt(geburt) und Schizophrenierisiko





McGrath *et al.* BMC Medicine 2004




van Os *et al.* Nature 2010

Montreal Imaging Stress Task







b




Lederbogen, Kirsch, Haddad et al.,
Nature 2011

Urbanität und Amygdalaaktivierung





Lederbogen, Kirsch, Haddad et al., **Nature** 2011

Stadtgeburt und Zingulum




Lederbogen, Kirsch, Haddad et al., **Nature** 2011

Ein Mechanismus für Gen-Umwelt-Interaktionen



Pezawas*, Meyer-Lindenberg* et al. **Nat Neurosci** 2005,
Pezawas*, Meyer-Lindenberg* et al. **Mol Psychiatry** 2008


Migration und Schizophrenie




Cantor-Grae and Selten Am J Psychiat 2005

Stressverarbeitung bei Migranten


A




B



C







D





Akdeniz*, Tost* et al., **JAMA Psychiatry** 2014


Konvergenz von Umwelt- und genetischen Risiken im perigenualen Zingulum



Dose-dependent effects of schizophrenia-related CNV (15q11.2(BP1-BP2)) on brain volume




Prosoziale Neuropeptide




- Molekulare Mediatoren prosozialen Verhaltens bei allen Säugetieren: Mutter-Kind-Bindung, Paarbindung, Vertrauen


- Beim Menschen nach nasaler Gabe zentral wirksam

- Potential für spezifische Synergien mit Psychotherapie






Zink et al., **J Neurosci** 2010




Meyer-Lindenberg et al., **Mol Psychiatry** 2008


Prosoziale Pharmakotherapie



Meyer-Lindenberg et al.,
Nat Rev Neurosci 2011




Tost et al. **PNAS** 2010



Kirsch et al.
J Neurosci 2005

Neuropsychotherapie



Danke



Bundesministerium
für Bildung
und Forschung



Deutsche
Forschungsgemeinschaft

DFG

NIMH

National Institute
of Mental Health



SEVENTH FRAMEWORK
PROGRAMME

NARSAD
*The World's Leading Charity Dedicated
to Mental Health Research*

- Tost, Zink, Akdeniz, Pezawas, Lederbogen, Haddad, Kirsch, Heinrichs, Walter, Grimm, Akdeniz
- Department of Psychiatry, WG Systems Neuroscience in Psychiatry

